Clearance of the non-permanent implant technology is backed by safety and efficacy results from the pivotal Expander-2 trial. On March 16, 2026, Prodeon Medical announced FDA 510(k) clearance for the ...

Combining ¹⁷⁷Lu-rosopatamab tetraxetan with ARPIs or followed by docetaxel met primary safety/dosimetry objectives in a 36-patient international lead-in and supported feasibility within contemporary ...

The discussion introduces how the treatment landscape for metastatic castration-sensitive prostate cancer has evolved, highlighting that patients are now living longer with metastatic disease and ...

Enzalutamide/leuprolide reduced metastasis or death versus leuprolide alone (HR 0.42) and improved overall survival (HR 0.597); enzalutamide monotherapy also improved ...